Justification of Pharmacological Choices for Diabetes Management

The selection of semaglutide for Ty was driven by several patient-specific factors. Her A1C of 8.5% indicated significant hyperglycemia, necessitating effective glucose lowering, for which GLP-1 receptor agonists are highly effective, capable of reducing A1C by 1–2%. Her advanced chronic kidney disease (CKD) with an eGFR of 26 mL/min/1.73 m² limited the use of many oral antidiabetic medications, but GLP-1 receptor agonists, like semaglutide, remain safe and effective for eGFR values above 15 mL/min/1.73 m². These agents also offer proven cardiovascular and renal benefits, crucial given the increased risks associated with diabetes and CKD. Expected benefits include gradual glucose control improvement, weight loss, and appetite reduction, with a low risk of hypoglycemia unless combined with insulin or sulfonylureas. Common gastrointestinal side effects can be managed with gradual dose titration and patient education. Ty's age and impaired renal function increased her susceptibility to hypoglycemia, making GLP-1 receptor agonists a safer choice compared to insulin or sulfonylureas due to their lower hypoglycemia risk profile. Finally, her history of medication nonadherence made the once-weekly formulation of semaglutide an advantageous choice for improving adherence.

The proposed treatment regimen focuses on individualized goals for A1C, which, for older adults with CKD and adherence challenges, may be less stringent (e.g., A1C <8%). Continuation of losartan 50 mg daily is recommended for renal and cardiovascular protection, given her well-controlled blood pressure and normal potassium levels. Close monitoring of blood glucose, A1C (every 3 months), renal function (every 3–6 months), and hypoglycemia risk is essential. Monitoring for gastrointestinal adverse effects, hydration status, pancreatitis, and gallbladder disease is also crucial. Comprehensive diabetes self-management education, using methods like 'teach-back,' and adherence strategies are vital. Patients should be educated on recognizing symptoms of dehydration, pancreatitis, and gallbladder disease. GLP-1 RAs should be avoided in individuals with a history of medullary thyroid carcinoma. The overall approach emphasizes considering patient history, risk factors, compliance ability, and providing thorough education.